Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Comparison of and Immune Reconstitution and Graft Versus Host Disease in 30mg/Kg Anti-T-Lymphocyte Globuline with 60mg/Kg ATLG As Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Myeloablative Peripheral Blood Stem Cell Transplantation

Radwan Massoud, Evgeny Klyuchnikov, Nico Gagelmann, Tatjana Zabelina, Wolschke Christine, Francis Ayuketang Ayuk, Ulrike Fritsche-Friedland, Axel R. Zander, Nicolaus Kröger

Blood (2021) 138 (Supplement 1): 3897.

https://doi.org/10.1182/blood-2021-153157

Published: 2021

Journal Articles

Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans

Blood (2020) 136 (12): 1442–1455.

https://doi.org/10.1182/blood.2020005957

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced Intensity Allogeneic Stem Cell Transplantation for Younger Patients with Myelofibrosis

Daniele Mannina, MD, Christine Wolschke, MD, Tatjana Zabelina, MD, Gaby Zeck, Ute-Marie von Pein, MD, Francis Ayuketang Ayuk, MD, Nicolaus Kroeger, MD

Blood (2018) 132 (Supplement 1): 5783.

https://doi.org/10.1182/blood-2018-99-112137

Published: 2018

Journal Articles

High Cure Rate By Allogeneic Stem Cell Transplantation for Myelofibrosis Patients Aged 65 or Older

Giulia Daghia, MD PhD, Tatjana Zabelina, MD, Gaby Zeck, Ute-Marie von Pein, MD, Maximilian Christopeit, MD, Christine Wolschke, MD, Francis Ayuketang Ayuk, MD, Nicolaus Kroeger, MD

Blood (2018) 132 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2018-99-113255

Published: 2018

Journal Articles

Ruxolitinib during Peritransplant Period for Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplantation Reduces Acute Graft-Versus-Host Disease

Nicolaus Kröger, MD, Sharifah Shahnaz Syed Abd Kadir, MD, Tatjana Zabelina, MD, Christine Wolschke, MD, Francis A. Ayuk, MD, Anita Badbaran, Maximilian Christopeit, MD

Blood (2016) 128 (22): 2242.

https://doi.org/10.1182/blood.V128.22.2242.2242

Published: 2016

Journal Articles

Impact of Pre-Transplant Ruxolitinib in Myelofibrosis Patients on Outcome after Allogeneic Stem Cell Transplantation

Sharifah Shahnaz Syed Abd Kadir, MD, Tatjana Zabelina, MD, Maximilian Christopeit, MD, Gerald G Wulf, MD, Eva Maria Wagner, MD, Martin Bornhäuser, MD, Thomas Schroeder, MD, Martina Crysandt, MD, Karin Mayer, MD, Matthias Stelljes, Anita Badbaran, Christine Wolschke, MD, Francis A. Ayuk, MD, Ioanna N Triviai, PhD, Dominik Wolf, MD, Nicolaus Kröger, MD

Blood (2016) 128 (22): 1950.

https://doi.org/10.1182/blood.V128.22.1950.1950

Published: 2016

Journal Articles

Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation

Blood (2015) 126 (23): 352.

https://doi.org/10.1182/blood.V126.23.352.352

Published: 2015

Journal Articles

Impact of Minimal Residual Disease after Allografting Detected By JAK2V617F, MPL or Calreticulin in Myelofibrosis Patients

Nicolaus Kroeger, Anita Badbaran, Tatjana Zabelina, MD, Maximilian Christopeit, MD, Christine Wolschke, MD, Francis Ayuk, MD, Axel R. Zander, Professor, Haefaa Alchalby, MD, Ulrike Bacher, Ioanna N Triviai, PhD, Boris Fehse, PhD

Blood (2015) 126 (23): 4343.

https://doi.org/10.1182/blood.V126.23.4343.4343

Published: 2015

Journal Articles

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis

Nicolaus Kröger, Toni Giorgino, Bart L. Scott, Markus Ditschkowski, Haefaa Alchalby, Francisco Cervantes, Alessandro Vannucchi, Mario Cazzola, Enrica Morra, Tatjana Zabelina, Margherita Maffioli, Arturo Pereira, Dietrich Beelen, H. Joachim Deeg, Francesco Passamonti

Blood (2015) 125 (21): 3347–3350.

https://doi.org/10.1182/blood-2014-10-608315

Published: 2015

Journal Articles

Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients

Nicolaus Kröger, MD, Toni Giorgino, PhD, Bart L Scott, MD, Marcus Ditschkowski, MD, Haefaa Alchalby, MD, Francisco Cervantes, MD PhD, Alessandro M. Vannucchi, MD, Mario Cazzola, MD, Enrica Morra, Tatjana Zabelina, MD, Margherita Maffioli, MD, Arturo Pereira, MD PhD, Dietrich Beelen, MD, H. Joachim Deeg, MD, Francesco Passamonti, MD

Blood (2014) 124 (21): 633.

https://doi.org/10.1182/blood.V124.21.633.633

Published: 2014

Journal Articles

Allogeneic Stem Cell Transplantation for CML in Accelerate or Blastic Phase

Elena V Morozova, MD PhD, Tatjana Zabelina, MD, Francis Ayuk, MD, Christine Wolschke, MD, Thomas Stübig, MD, Sergey N Bondarenko, Alexandr L. Alianskii, MD, Axel R. Zander, MD, Boris Afanasyev, MD, Nicolaus Kröger, MD

Blood (2014) 124 (21): 1220.

https://doi.org/10.1182/blood.V124.21.1220.1220

Published: 2014

Journal Articles

Quality Of Life After Allogeneic Stem Cell Transplantation In Patients With Myelofibrosis (CMWP of EBMT)

Nora Machate, Haefaa Alchalby, MD, Susanne Sehner, Tatjana Zabelina, MD, Daniel Wolff, MD, Guido Kobbe, MD, Martin Bornhäuser, MD, Herrad Baurmann, MD, Wolfgang A Bethge, MD, Gerald Wulf, MD, Axel R. Zander, MD, Nicolaus Kröger, MD

Blood (2013) 122 (21): 2974.

https://doi.org/10.1182/blood.V122.21.2974.2974

Published: 2013

Journal Articles

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Nicolaus Kröger, MD, Haefaa Alchalby, MD, Tatjana Zabelina, MD, Hans-Michael Kvasnicka, MD, Juergen Thiele, MD, PhD, Guntram Büsche, MD, Hans Kreipe, MD

Blood (2013) 122 (21): 2078.

https://doi.org/10.1182/blood.V122.21.2078.2078

Published: 2013

Journal Articles

Ruxolitinib As Pretreatment Before Allogeneic Stem Cell Transplantation For Myelofibrosis

Nicolaus Kröger, MD, Haefaa Alchalby, MD, Markus Ditschkowski, MD, Dominik Wolf, MD, Gerald Wulf, MD, Tatjana Zabelina, MD, Christine Wolschke, MD, Thomas Stübig, MD, Francis Ayuk, MD

Blood (2013) 122 (21): 392.

https://doi.org/10.1182/blood.V122.21.392.392

Published: 2013

Journal Articles

Impact Of Conditioning Regimen, Donor Source, and DIPSS Score On Outcome Of Allogeneic Hematopoietic Stem Cell Transplantation For Myelofibrosis

Nicolaus Kröger, MD, Markus Ditschkowski, MD, Bart L Scott, MD, Tatjana Zabelina, MD, Haefaa Alchalby, MD, Dietrich Beelen, MD, H. Joachim Deeg, MD

Blood (2013) 122 (21): 712.

https://doi.org/10.1182/blood.V122.21.712.712

Published: 2013

Journal Articles

Effective Prevention of Acute and Chronic Graft-Versus-Host Disease with Anti-Lymphocyte Globulin (ATG) without Increase of Relapse in HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation.

Nicolaus Kröger, Tatjana Zabelina, Francis Ayuk, Haefaa Alchalby, MD, Christine Wolschke, Thomas Stübig, Evgeny Klyuchnikov, Jürgen Berger, Axel R. Zander, MD

Blood (2012) 120 (21): 3055.

https://doi.org/10.1182/blood.V120.21.3055.3055

Published: 2012

Journal Articles

Impact of ASXL1 Mutations On Outcome After Reduced Intensity Allograft in Patients with Myelofibrosis

Nicolaus Kröger, Christian Koenecke, Haefaa Alchalby, MD, Tatjana Zabelina, MD, Robin Bollin, Marten Gehlhaar, Vera Dobbernack, Sofia Kade, Liu Huang, Arnold Ganser, Francis Ayuk, MD, Christine Wolschke, MD, Felicitas Thol, MD, Michael Heuser, MD

Blood (2012) 120 (21): 1740.

https://doi.org/10.1182/blood.V120.21.1740.1740

Published: 2012

Journal Articles

Prognostic Impact of Physiological B-Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post-Transplant Period in Patients with AML

Ulrike Bacher, MD, Maximilian Christopeit, MD, Anneke Heiland, Mascha Binder, MD, Tatjana Zabelina, MD, Francis Ayuk, MD, Christiane Horn, Torsten Haferlach, MD, Carsten Bokemeyer, M.D., Nicolaus Kroeger, MD

Blood (2012) 120 (21): 1406.

https://doi.org/10.1182/blood.V120.21.1406.1406

Published: 2012

Journal Articles

Post-Allogeneic Monitoring with Molecular Markers Detected by Pre-Transplant Next Generation Sequencing (NGS) Predicts Clinical Relapse in Patients with Chronic Myelomonocytic Leukemia (CMML)

Nicolaus Kröger, Thomas Schroeder, MD, Tatjana Zabelina, MD, Anita Badbaran, Ulrike Bacher, MD, Guido Kobbe, MD, Susanne Schnittger, PhD, Alexander Kohlmann, PhD, Torsten Haferlach, MD

Blood (2012) 120 (21): 4212.

https://doi.org/10.1182/blood.V120.21.4212.4212

Published: 2012

Journal Articles

Measurement of Liver Iron Concentration by Quantum Interference Device Biosusceptometry (SQUID) Validates Serum Ferritin As Prognostic Parameter for Allogeneic Stem Cell Transplantation

Nicole Jacobi, MD, MS, Regine Grosse, MD, Tugce Aktas, Lena Herich, Peter Nielsen, MD, Roland Fischer, PhD, Tatjana Zabelina, Ulrike Bacher, MD, Nicolaus Kroeger, Sr., MD

Blood (2011) 118 (21): 1018.

https://doi.org/10.1182/blood.V118.21.1018.1018

Published: 2011

NARROW

Comparison of and Immune Reconstitution and Graft Versus Host Disease in 30mg/Kg Anti-T-Lymphocyte Globuline with 60mg/Kg ATLG As Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Myeloablative Peripheral Blood Stem Cell Transplantation

Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans

Reduced Intensity Allogeneic Stem Cell Transplantation for Younger Patients with Myelofibrosis

High Cure Rate By Allogeneic Stem Cell Transplantation for Myelofibrosis Patients Aged 65 or Older

Ruxolitinib during Peritransplant Period for Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplantation Reduces Acute Graft-Versus-Host Disease

Impact of Pre-Transplant Ruxolitinib in Myelofibrosis Patients on Outcome after Allogeneic Stem Cell Transplantation

Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation

Impact of Minimal Residual Disease after Allografting Detected By JAK2V617F, MPL or Calreticulin in Myelofibrosis Patients

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis

Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients

Allogeneic Stem Cell Transplantation for CML in Accelerate or Blastic Phase

Quality Of Life After Allogeneic Stem Cell Transplantation In Patients With Myelofibrosis (CMWP of EBMT)

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Ruxolitinib As Pretreatment Before Allogeneic Stem Cell Transplantation For Myelofibrosis

Impact Of Conditioning Regimen, Donor Source, and DIPSS Score On Outcome Of Allogeneic Hematopoietic Stem Cell Transplantation For Myelofibrosis

Effective Prevention of Acute and Chronic Graft-Versus-Host Disease with Anti-Lymphocyte Globulin (ATG) without Increase of Relapse in HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation.

Impact of ASXL1 Mutations On Outcome After Reduced Intensity Allograft in Patients with Myelofibrosis

Prognostic Impact of Physiological B-Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post-Transplant Period in Patients with AML

Post-Allogeneic Monitoring with Molecular Markers Detected by Pre-Transplant Next Generation Sequencing (NGS) Predicts Clinical Relapse in Patients with Chronic Myelomonocytic Leukemia (CMML)

Measurement of Liver Iron Concentration by Quantum Interference Device Biosusceptometry (SQUID) Validates Serum Ferritin As Prognostic Parameter for Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only